Sinopharm Group Co Ltd
HKEX:1099

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
HKEX:1099
Watchlist
Price: 20.56 HKD 0.49% Market Closed
Market Cap: 64.2B HKD

Sinopharm Group Co Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sinopharm Group Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Sinopharm Group Co Ltd
HKEX:1099
Free Cash Flow
¥17.1B
CAGR 3-Years
234%
CAGR 5-Years
52%
CAGR 10-Years
16%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Free Cash Flow
¥3.2B
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Free Cash Flow
¥2.1B
CAGR 3-Years
-17%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
C
China National Medicines Corp Ltd
SSE:600511
Free Cash Flow
¥567.9m
CAGR 3-Years
-25%
CAGR 5-Years
-12%
CAGR 10-Years
12%
Huadong Medicine Co Ltd
SZSE:000963
Free Cash Flow
¥2B
CAGR 3-Years
16%
CAGR 5-Years
3%
CAGR 10-Years
32%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Free Cash Flow
¥1.3B
CAGR 3-Years
-13%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

Sinopharm Group Co Ltd
Glance View

Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.

Intrinsic Value
89.16 HKD
Undervaluation 77%
Intrinsic Value
Price

See Also

What is Sinopharm Group Co Ltd's Free Cash Flow?
Free Cash Flow
17.1B CNY

Based on the financial report for Jun 30, 2025, Sinopharm Group Co Ltd's Free Cash Flow amounts to 17.1B CNY.

What is Sinopharm Group Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
16%

Over the last year, the Free Cash Flow growth was 2%. The average annual Free Cash Flow growth rates for Sinopharm Group Co Ltd have been 234% over the past three years , 52% over the past five years , and 16% over the past ten years .

Back to Top